

KRN-633

Catalog No: tcsc0220



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

286370-15-8

Formula:

$C_{20}H_{21}ClN_4O_4$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

VEGFR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 8 mg/mL (19.19 mM)

Observed Molecular Weight:

416.86


Product Description

KRN-633 is a potent **VEGFR** inhibitor with **IC₅₀**s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.

IC50 & Target: IC50: 170 nM (VEGFR1), 160 nM (VEGFR2), 125 nM (VEGFR3)^[1]

In Vitro: KRN-633 inhibits tyrosine phosphorylation of VEGFR-1, VEGFR2, c-Kit, and PDGFR- β (IC_{50} =11.7, 1.16, 8.01, 130 nM) in human umbilical vein endothelial cells. KRN-633 also inhibits the VEGF-driven proliferation of HUVECs (IC_{50} =14.9 nM). KRN-633 suppresses capillary tube formation of endothelial cells^[1].

In Vivo: KRN-633 inhibits tumor growth in several tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN-633 also causes the regression of some well-established tumors and those that have regrown after the cessation of treatment. KRN-633 is well tolerated and has no significant effects on body weight or the general health of the animals. Histologic analysis of tumor xenografts treated with KRN-633 reveals a reduction in the number of endothelial cells in non-necrotic areas and a decrease in vascular permeability^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!